

25-hydroxyvitamin D₃ (RAYALDEE)

Diagnosis Considered for Coverage:

- Secondary Hyperparathyroidism due to Chronic Kidney Disease

Coverage Criteria:

For diagnosis listed above:

- Patient has chronic kidney disease stage 3 or 4, **and**
- Patient is NOT currently receiving dialysis, **and**
- Patient has vitamin D deficiency with a baseline serum total 25(OH) vitamin D level below 30 ng/mL, **and**
- Dose does not exceed 60 mcg per day.

Coverage Duration: one year

References:

1. Prescribing Information. Rayaldee. OPKO Pharmaceuticals Inc. 12.2019

Effective Date: 11/30/2022